{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:09:06Z","timestamp":1773202146785,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejca.2025.115794","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:35:12Z","timestamp":1758587712000},"page":"115794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial"],"prefix":"10.1016","volume":"230","author":[{"given":"Shaohua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2025.115794_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ejca.2025.115794_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115794_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2025.115794_bib4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115794_bib5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer Version 2.2024 \u2014 March 11, 2024."},{"key":"10.1016\/j.ejca.2025.115794_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese society of clinical oncology (CSCO) breast cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2025.115794_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2025.115794_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ajco.12748","article-title":"Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies","volume":"14","author":"Khosravi-Shahi","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115794_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4143\/crt.2017.562","article-title":"Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01)","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2025.115794_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115794_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115794_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ejca.2025.115794_bib13","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.ejca.2025.115794_bib14","unstructured":"Guideline Recommendations for HER2 Detection in Breast Cancer Group. [Guidelines for HER2 detection in breast cancer, the 2014 version]. Zhonghua Bing Li Xue Za Zhi, 2014; 43(4): 262\u2013267."},{"issue":"2","key":"10.1016\/j.ejca.2025.115794_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115794_bib16","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). Accessed Mar 1, 2023. \u3008https:\/\/www.meddra.org\u3009."},{"key":"10.1016\/j.ejca.2025.115794_bib17","unstructured":"National Cancer Institute. Common terminology criteria for adverse events, version 5.0. 2017. \u3008https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50\u3009."},{"issue":"10411","key":"10.1016\/j.ejca.2025.115794_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115794_bib19","article-title":"NSABP B-47: a randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer","volume":"31","author":"Fehrenbacher","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9769","key":"10.1016\/j.ejca.2025.115794_bib20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2025.115794_bib21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115794_bib22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","article-title":"Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial","volume":"133","author":"Brufsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.ejca.2025.115794_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115794_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2025.115794_bib25","unstructured":"Herceptin\u00a9R (trastuzumab): EPAR - Product Information. Roche Pharma AG; First published in EMA: 2010. \u3008http:\/\/www.ema.europa.eu\u3009."},{"key":"10.1016\/j.ejca.2025.115794_bib26","unstructured":"HERCEPTIN\u00a9R (trastuzumab) for injection. Prescribing information. Genentech, Inc; Initial U.S. Approval: 1998. \u3008http:\/\/www.fda.gov\/\u3009."},{"key":"10.1016\/j.ejca.2025.115794_bib27","unstructured":"Perjeta\u00a9R (pertuzumab): EPAR - Product Information. Roche Pharma AG; First published in EMA: 2013. http:\/\/www.ema.europa.eu."},{"key":"10.1016\/j.ejca.2025.115794_bib28","unstructured":"PERJETA\u00a9R (pertuzumab) injection. Prescribing information. Genetech, Inc; Initial U.S. Approval: 2012. http:\/\/www.fda.gov\/."},{"key":"10.1016\/j.ejca.2025.115794_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin e (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ejca.2025.115794_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2019.100795","article-title":"Neurosteroids and neuropathic pain management: basic evidence and therapeutic perspectives","volume":"55","author":"Meyer","year":"2019","journal-title":"Front Neuroendocr"},{"issue":"4","key":"10.1016\/j.ejca.2025.115794_bib31","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1254\/jphs.FP0072181","article-title":"Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNFalpha)-positive mast cells in rats with a painful peripheral neuropathy","volume":"106","author":"Hayashi","year":"2008","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.ejca.2025.115794_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in previously treated asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study","volume":"31","author":"Yamashita","year":"2024","journal-title":"Breast Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:03:44Z","timestamp":1773126224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"alternative-id":["S0959804925005805"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115794","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115794"}}